The company’s system is placed in the subclavian vein, a blood vessel that runs under the collar bone bringing deoxygenated ...

RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ: GCTK), a medical technology company, announced the successful completion of its first in human clinical study for a novel continuous glucose monitoring ...

This week also saw Glucotrack aim to raise $3 million through a public share offering, with about 2.6 million shares of common stock priced at $1.15 apiece.

Glucotrack (GCTK) announced the pricing of a “best efforts” public offering of approximately 2.6M shares of common stock. The offering price of each share of common stock is $1.15, The gross ...

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose ...

Glucotrack (NASDAQ:GCTK) on Tuesday reported the successful completion of its first in human clinical study, sending shares up ~60% in the morning trade. This study represents first real-time ...

At $1.15 a share, the offering is being done on a "best efforts" basis. Subject to usual circumstances, the business anticipates the deal to conclude on or around Feb. 5. The only placement agent ...

Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...

As you can see from the chart above the percentage of shares that are sold short for GlucoTrack has grown since its last report. This does not mean that the stock is going to fall in the near-term ...